Senzime - Strengthening EU prospects
Redeye reviews its take on Senzime following its establishment of a direct sales force in Germany while also factoring in a continued effect on its sales prospects due to Corona. We make slight downward adjustments to our shorter-term sales estimates, but our confidence in Senzime's ability to reach its SEK 200m sales target in 2023 remains. We repeat our positive view on the share and see a significant upside of 60%, likely to be ignited in H2 on the back of impressive revenue growth.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/